Tamara van Donge

Chapter 5 90 References 1. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstetrics and gynecology. 2016;128(1):4. 2. Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. The BMJ. 2017;358:j3326. 3. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics and gynecology. 2014;123(5):997. 4. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology. 2015;40(1):61. 5. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Paper presented at: Seminars in perinatology2015. 6. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. Jama. 2012;307(18):1934-1940. 7. Jones HE, Fielder A. Neonatal abstinence syndrome: Historical perspective, current focus, future directions. Preventive Medicine. 2015;80:12-17. 8. Finnegan L, Connaughton JJ, Kron R, Emich J. Neonatal abstinence syndrome: assessment and management. Addictive diseases. 1975;2(1-2):141-158. 9. Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. The American journal of drug and alcohol abuse. 1981;8(2):203-213. 10. Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. The Journal of pediatrics. 2014;165(3):440- 446. 11. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012:peds. 2011-3212. 12. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2010;10(10). 13. Davis JM, Shenberger J, Terrin N, et al. Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. JAMA pediatrics. 2018. 14. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatric Clinics. 2012;59(5):1147-1165. 15. Wiles JR, Isemann B, Mizuno T, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. The Journal of pediatrics. 2015;167(6):1214-1220. e1213. 16. Kharasch ED. Current concepts in methadone metabolism and transport. Clinical pharmacology in drug development. 2017;6(2):125-134. 17. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Clinical pharmacokinetics. 2002;41(14):1153-1193. 18. Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. The Journal of Clinical Pharmacology. 2013;53(3):305-313. 19. van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. The Journal of Clinical Pharmacology. 2018;58:S10-S25. 20. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady‐state pharmacokinetics of (R)‐and (S)‐methadone in methadone maintenance patients. British journal of clinical pharmacology. 2000;50(5):427-440.